ACS Infectious Diseases · 2021 · 46 citations · 33 references
Life SciencesInfectious DiseasesPharmacologyIon Channel BiophysicsMolecular VirologyVirologyAntiviral PharmacologyCalcium SignalingIntracellular Calcium SignalingViral EntryVirus EntryCa2+ SignalingCalcium Channel PharmacologyFusion Peptide FunctionL-type Calcium CurrentSars-cov-2 InfectionSevere Acute Respiratory SyndromeViral Fusion InhibitorsViral Membrane Fusion
COVID-19 is caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus (CoV)-2 (SARS-CoV-2). The virus is responsible for an ongoing pandemic and concomitant public health crisis around the world. While vaccine development is proving to be highly successful, parallel drug development approaches are also critical in the response to SARS-CoV-2 and other emerging viruses. Coronaviruses require Ca2+ ions for host cell entry, and we have previously shown that Ca2+ modulates the interaction of the viral fusion peptide with host cell membranes. In an attempt to accelerate drug repurposing, we tested a panel of L-type calcium channel blocker (CCB) drugs currently developed for other conditions to determine whether they would inhibit SARS-CoV-2 infection in cell culture. All the CCBs tested showed varying degrees of inhibition, with felodipine and nifedipine strongly limiting SARS-CoV-2 entry and infection in epithelial lung cells at concentrations where cell toxicity was minimal. Further studies with pseudotyped particles displaying the SARS-CoV-2 spike protein suggested that inhibition occurs at the level of virus entry. Overall, our data suggest that certain CCBs have the potential to treat SARS-CoV-2 infections and are worthy of further examination for possible treatment of COVID-19.
33
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Jonathan Grein, Norio Ohmagari, Daniel D. Shin et al. · New England Journal of Medicine · 2020 · 2.9K citations · Full text
A human monoclonal antibody blocking SARS-CoV-2 infection
Chunyan Wang, Wentao Li, Dubravka Drabek et al. · Nature Communications · 2020 · 1.2K citations · Full text